Nov. 30, 2023 7:51 am ET
AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.
AbbVie on Thursday said it will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday’s closing price of $16.06 for the Waltham, Mass., pharmaceutical company.
Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Source: finance.yahoo.com
Related posts:
FTX spox O'Leary says he called SBF and demanded, 'Where is the money, Sam?'
Devon Energy Mulls M&A Options With Marathon, CrownRock
Twitter Adopts ‘Poison Pill’ to Ward Off Musk Takeover
Jamie Dimon reveals what he would do as president: Tax people like Bill Ackman more
Treasury bond auctions have been ugly lately, and weak demand could be a 'canary in the coal mine'